Results 91 to 100 of about 25,845 (281)

Flunitrazepam increases the risk of lamotrigine‐induced cutaneous adverse reactions: Combined analysis of medical big data and clinical research

open access: yesPsychiatry and Clinical Neurosciences, EarlyView.
Aim The concomitant use of lamotrigine and valproic acid, a uridine diphosphate (UDP)‐glucuronosyltransferase inhibitor, is a known risk factor for lamotrigine‐induced rashes, which may develop into fatal or severe cutaneous adverse reactions. No drugs other than valproic acid have been shown to increase lamotrigine concentrations in humans by ...
Hiroshi Bando   +21 more
wiley   +1 more source

Revisiting In‐Gas Transformations of Quinate Conjugates Through the LC‐qTOF‐MS and Molecular Networking Topology

open access: yesRapid Communications in Mass Spectrometry, Volume 39, Issue 16, 30 August 2025.
ABSTRACT Rationale The emergence of computational metabolomics tools such as molecular networking and machine learning–based platforms like SIRIUS has significantly advanced MS‐based metabolomics studies. These tools enable rapid metabolite identification by deciphering complex fragmentation patterns and chemical transformations occurring during mass ...
Nakisani Babra Moyo   +1 more
wiley   +1 more source

Divergent Expression and Metabolic Functions of Human Glucuronosyltransferases through Alternative Splicing

open access: yesCell Reports, 2016
Maintenance of cellular homeostasis and xenobiotic detoxification is mediated by 19 human UDP-glucuronosyltransferase enzymes (UGTs) encoded by ten genes that comprise the glucuronidation pathway.
Michèle Rouleau   +10 more
doaj   +1 more source

The estrobolome: Estrogen‐metabolizing pathways of the gut microbiome and their relation to breast cancer

open access: yesInternational Journal of Cancer, Volume 157, Issue 4, Page 599-613, 15 August 2025.
Abstract Increasing evidence links the gut microbiome to carcinogenesis. Disruptions in estrogen regulation by the estrobolome—gut microbiota with estrogen‐related functions—may promote breast cancer. However, precise information on estrobolome targets and their underlying mechanisms is limited. This review identifies relevant targets for measuring the
Ashley H. Larnder   +2 more
wiley   +1 more source

Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus

open access: yesBritish Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2390-2400, August 2025.
Aims To characterize the pharmacokinetics (PK) and PK/pharmacodynamics (PD) regarding glycosylated haemoglobin (HbA1c) lowering using the paediatric data from DINAMO and to assess differences compared with adults. Methods Population PK and PK/PD models previously developed for empagliflozin in adults and adolescents were re‐estimated in a Bayesian ...
Juliane Rascher   +7 more
wiley   +1 more source

Utilization of carbon catabolite repression for efficiently biotransformation of anthraquinone O-glucuronides by Streptomyces coeruleorubidus DM

open access: yesFrontiers in Microbiology
Carbon catabolite repression (CCR) is a highly conserved mechanism that regulates carbon source utilization in Streptomyces. CCR has a negative impact on secondary metabolite fermentation, both in industrial and research settings.
Chen Tao   +8 more
doaj   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

open access: yesClinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 605-613, August 2025.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy